.webp)
Search results
Accelerate therapeutic discovery and maximize ROI with our streamlined platform, fully integrated across your entire portfolio. Use digital and decentralized trials to scale your pipeline beyond what's possible with traditional clinical trials.
With MarketsandMarkets projecting the global electronic Clinical Outcome Assessments (eCOA) solutions market to grow at compound annual growth rate (CAGR) of 16.1% each year until 2030, it’s clear the eCOA has made its impact within the clinical research landscape. Yet despite growing adoption, electronic Clinical Outcome Assessments (eCOA) are still surrounded by misconceptions that hinder their full potential. From concerns about patient usability to assumptions about cost and implementation timelines, these myths can create hesitation among sponsors and research teams alike.Thus, we’re here to cut through the noise and set the record straight with a summary of a recent webinar featuring speakers from Transcelerate and Medable.
Join leading clinical experts as they discuss and debunk the top 5 myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter, faster decisions.
Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.
Gain a quick overview of what top trends and topics dominated DIA 2023.
With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.
Discover how Medable helped digitize and standardize a client's participant pain body maps for a diabetic polyneuropathy trial.
The TOGETHERCare App was created to help caregivers implement home-based care for cancer survivors. Review the Medable TOGETHERCare app Privacy Statement here.
Medable's Access app was created during the epidemiological emergency created by the SARS-CoV-2 virus. Review the app privacy statement here.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Medable is an end-to-end, cloud-based platform with a scalable suite of tools that allows sponsors, patients, providers & CRO's to work together as a team in clinical trials. Our solutions enable more efficient workflows and patient-focused data collection. Click to learn more.
This Privacy Center is intended to help you identify the Medable privacy practices & Privacy Statements which apply to your use of Medable websites/applications.
This Privacy Center is intended to help you identify the Medable privacy practices & Privacy Statements which apply to your use of Medable websites/applications.
This Privacy Center is intended to help you identify the Medable privacy practices & Privacy Statements which apply to your use of Medable websites/applications.
See why many of the top pharma are focused on building the "next model" of clinical trial conduct using foundational platforms.
This Terms of Use is intended to help you identify the Medable privacy practices & Privacy Statements which apply to your use of Medable websites/applications.
These Trademark and Copyright Guidelines (“Guidelines”) apply to licensees, developers, customers, and authorized parties (collectively, “You”) who wish to use Medable Inc and its affiliates (collectively, “Medable”)
Learn how Medable's eCOA (electronic clinical outcome assessment) solution was able to deliver >90% adherence and scalability for a top pharmaceutical weight management clinical trial.
Contact Medable for a demo and to learn more about DCT certification, careers, and support. Medable, per Everest Group Peak matrix, is the top decentralized clinical trial company.
Debunk the most prevalent electronic informed consent myths and reach a deeper understanding of decentralized clinical trials.
Within biosample storage, a “nightmare scenario” exists that Medable and our clients discuss regularly. Some years ago, a sponsor with tens of thousands of biosample specimens identified that they had lost the ability to link their biobank samples' documented consent for storage (and further research). The consent for these samples was taken on paper, but a system to collate and file the consent data attributed to each specimen was not implemented. When the organization couldn’t find the paper consent, they were forced to dispose of thousands of biospecimens, losing the ability to conduct valuable research and potentially millions of dollars of lost IP. At Medable, we have built our eConsent solution, Total Consent, to easily capture consent for storing biosample specimens. As a robust and complete consent management solution, Total Consent solves the problems inherent in biospecimen consent storage by directly linking a consent eSignature to a sample and making this consent object easily extractable for long-term storage. This allows organizations to collect and collate biosample consents across multiple studies, enabling them to create their digital biobank.
A top 10 pharmaceutical company looked to Medable to streamline participant burden and enhance site and team experience in oncology trials, while establishing a scalable template for future trials in oncology and other areas.
Learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.
A top-3 contract research organization (CRO) and a top-10 pharmaceutical company partnered with Medable to help accelerate the speed, scale, and standardization of their eCOA trials.The two organizations had been hampered by lengthy configuration timelines, inconsistent designs across studies, and siloed processes between sponsors and their CRO partners.By centralizing the sponsor’s preferred instruments and configurations into a reusable digital library, Medable enabled the CRO to rapidly accelerate its portfolio development and initiate new studies without starting them “from scratch.”
Join Medable's Mohammed Ali, Chief Domain Expert and Shubha Govil, SVP of Product Management,Platform to hear how top pharma teams have adopted digital technology across a platform to reduce costs and accelerate time to market.
Medable worked with a top 5 pharma company to increase the safety of patients as anti-cancer treatments may cause pulmonary toxicity, ranging from asymptomatic radiological changes to respiratory failure, and is considered a common side effect.
See how customers have had success with Medable, our trial platform, and our teams.
Streamline your clinical trial and generate high-quality data with a #1 rated, easy-to-use platform, offered in over 60 countries and 120 languages. Book a demo to learn more.
In this webinar, learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.
This Televisit App facilitates visits between a healthcare provider & patient in a HIPPA-secure manner. Review the Medable Televisit app Privacy Statement here.
The Financial Conflict of Interest Policy for Medable regarding Public Health Service funded research.
Melissa Opraseuth, SVP of Operations at Cloudmed, sits down to chat about the future of pharma and how to recruit and retain more diverse patients.
Learn how we can help you navigate the complexities of clinical operations so that you can meet your study's milestones faster and easier.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
The recent release (May 2023) of the FDA's Decentralized Clinical Trial (DCT) Draft Guidance has sparked a wave of excitement and anticipation within the field of clinical trials. This long-awaited guidance represents a significant milestone in the evolution of clinical trial methodologies, signaling clear support for the global shift towards expanded trial models. This guidance reinforces the FDA's commitment to supporting innovation in clinical trial design and emphasizes the need for careful consideration, training, oversight, and risk management for successful DCT implementation.
A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan. Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable to develop an initiative to enhance the region’s patient and site experience.
A top, global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
The partnership between Medable, U.S. Renal Care, and the top ten pharmaceutical sponsor exemplifies the transformative power of Medable’s Total Consent solution in clinical trials. By overcoming common misconceptions around participant age, cost, and complexity, Medable’s platform proved to be a flexible, fast, and efficient solution for the elderly renal care population. U.S. Renal Care sought to use Medable’s Total Consent (Medable’s eConsent solution) for an investigator-initiated trial. The phase 4 trial, which was funded by a top 10 pharmaceutical company, sought to enroll elderly participants suffering from Anemia ESKD (End Stage Kidney Disease) across 476 site users. The trial would be managed by three central principal investigators (PIs).
See how Medable was able to increase study startup speed for one customer by 50%.